In heart failure patients, there was a lack of changes in cardiac imaging parameters correlates with the lack of impact on outcomes among patients with pre-existing heart failure in major GLP-1 receptor agonist trials
Conversely, the correlation between obesity and outcomes in triple-negative and HER2-positive subtypes remains less conclusive [7]
Wegovy costs approximately $1,300 to $1,500 per month
Many patients benefit from smaller, frequent meals rather than three large ones
These cardioprotective properties make both of these new medications a promising therapeutic agent for preventing & managing cardiovascular disease such as heart attack, heart failure, & atherosclerosis-associated events such as stroke
The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence